1. Biochemistry and Chemical Biology
  2. Structural Biology and Molecular Biophysics

Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol

  1. Kelly A Manthei
  2. Shyh-Ming Yang
  3. Bolormaa Baljinnyam
  4. Louise Chang
  5. Alisa Glukhova
  6. Wenmin Yuan
  7. Lita A Freeman
  8. David J Maloney
  9. Anna Schwendeman
  10. Alan T Remaley
  11. Ajit Jadhav
  12. John JG Tesmer  Is a corresponding author
  1. University of Michigan, United States
  2. National Institutes of Health, United States
  3. National Heart, Lung, and Blood Institute, National Institutes of Health, United States
  4. Purdue University, United States
https://doi.org/10.7554/eLife.41604
Share this article
Cite this article
  1. Kelly A Manthei
  2. Shyh-Ming Yang
  3. Bolormaa Baljinnyam
  4. Louise Chang
  5. Alisa Glukhova
  6. Wenmin Yuan
  7. Lita A Freeman
  8. David J Maloney
  9. Anna Schwendeman
  10. Alan T Remaley
  11. Ajit Jadhav
  12. John JG Tesmer
(2018)
Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol
eLife 7:e41604.
https://doi.org/10.7554/eLife.41604
  2. Download BibTeX
  3. Download .RIS

Abstract

Lecithin:cholesterol acyltransferase (LCAT) and LCAT-activating compounds are being investigated as treatments for coronary heart disease (CHD) and familial LCAT deficiency (FLD). Herein we report the crystal structure of human LCAT in complex with a potent piperidinylpyrazolopyridine activator and an acyl intermediate-like inhibitor, revealing LCAT in an active conformation. Unlike other LCAT activators, the piperidinylpyrazolopyridine activator binds exclusively to the membrane-binding domain (MBD). Functional studies indicate that the compound does not modulate the affinity of LCAT for HDL, but instead stabilizes residues in the MBD and facilitates channeling of substrates into the active site. By demonstrating that these activators increase the activity of an FLD variant, we show that compounds targeting the MBD have therapeutic potential. Our data better define the substrate binding site of LCAT and pave the way for rational design of LCAT agonists and improved biotherapeutics for augmenting or restoring reverse cholesterol transport in CHD and FLD patients.

Data availability

The atomic coordinates and structure factors for the complex have been deposited in the PDB with accession code 6MVD.

The following data sets were generated

Article and author information

Author details

  1. Kelly A Manthei

    Life Sciences Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3874-8228

  2. Shyh-Ming Yang

    National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1928-136X

  3. Bolormaa Baljinnyam

    National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Louise Chang

    Life Sciences Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Alisa Glukhova

    Life Sciences Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Wenmin Yuan

    Department of Pharmaceutical Science, Biointerfaces Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Lita A Freeman

    Lipoprotein Metabolism Section, Cardiovascular-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. David J Maloney

    National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. Anna Schwendeman

    Department of Pharmaceutical Science, Biointerfaces Institute, University of Michigan, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  10. Alan T Remaley

    Lipoprotein Metabolism Section, Cardiovascular-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.

  11. Ajit Jadhav

    National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7955-1451

  12. John JG Tesmer

    Department of Biological Sciences, Purdue University, West Lafayette, United States
    For correspondence
    jtesmer@purdue.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1125-3727

Funding

National Heart, Lung, and Blood Institute

  • Alan T Remaley

National Center for Advancing Translational Sciences (Division of Preclinical Innovation)

  • Ajit Jadhav

American Heart Association (15POST24870001)

  • Kelly A Manthei

National Institutes of Health (F32HL131288)

  • Kelly A Manthei

American Heart Association (16POST27760002)

  • Wenmin Yuan

National Institutes of Health (HL071818)

  • John JG Tesmer

National Institutes of Health (HL122416)

  • John JG Tesmer

American Heart Association (13SDG17230049)

  • Anna Schwendeman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,666
    views
  • 363
    downloads
  • 41
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kelly A Manthei
  2. Shyh-Ming Yang
  3. Bolormaa Baljinnyam
  4. Louise Chang
  5. Alisa Glukhova
  6. Wenmin Yuan
  7. Lita A Freeman
  8. David J Maloney
  9. Anna Schwendeman
  10. Alan T Remaley
  11. Ajit Jadhav
  12. John JG Tesmer
(2018)
Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol
eLife 7:e41604.
https://doi.org/10.7554/eLife.41604

Share this article

https://doi.org/10.7554/eLife.41604

Categories and tags

Further reading

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics

    High-resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discovery

    Conor J Howard, Nathan S Abell ... Nathan B Lubock
    Research Article

    Deep Mutational Scanning (DMS) is an emerging method to systematically test the functional consequences of thousands of sequence changes to a protein target in a single experiment. Because of its utility in interpreting both human variant effects and protein structure-function relationships, it holds substantial promise to improve drug discovery and clinical development. However, applications in this domain require improved experimental and analytical methods. To address this need, we report novel DMS methods to precisely and quantitatively interrogate disease-relevant mechanisms, protein-ligand interactions, and assess predicted response to drug treatment. Using these methods, we performed a DMS of the melanocortin-4 receptor (MC4R), a G-protein-coupled receptor (GPCR) implicated in obesity and an active target of drug development efforts. We assessed the effects of >6600 single amino acid substitutions on MC4R’s function across 18 distinct experimental conditions, resulting in >20 million unique measurements. From this, we identified variants that have unique effects on MC4R-mediated Gαs- and Gαq-signaling pathways, which could be used to design drugs that selectively bias MC4R’s activity. We also identified pathogenic variants that are likely amenable to a corrector therapy. Finally, we functionally characterized structural relationships that distinguish the binding of peptide versus small molecule ligands, which could guide compound optimization. Collectively, these results demonstrate that DMS is a powerful method to empower drug discovery and development.

    1. Biochemistry and Chemical Biology

    Coordinated regulation of chemotaxis and resistance to copper by CsoR in Pseudomonas putida

    Meina He, Yongxin Tao ... Wenli Chen
    Research Article

    Copper is an essential enzyme cofactor in bacteria, but excess copper is highly toxic. Bacteria can cope with copper stress by increasing copper resistance and initiating chemorepellent response. However, it remains unclear how bacteria coordinate chemotaxis and resistance to copper. By screening proteins that interacted with the chemotaxis kinase CheA, we identified a copper-binding repressor CsoR that interacted with CheA in Pseudomonas putida. CsoR interacted with the HPT (P1), Dimer (P3), and HATPase_c (P4) domains of CheA and inhibited CheA autophosphorylation, resulting in decreased chemotaxis. The copper-binding of CsoR weakened its interaction with CheA, which relieved the inhibition of chemotaxis by CsoR. In addition, CsoR bound to the promoter of copper-resistance genes to inhibit gene expression, and copper-binding released CsoR from the promoter, leading to increased gene expression and copper resistance. P. putida cells exhibited a chemorepellent response to copper in a CheA-dependent manner, and CsoR inhibited the chemorepellent response to copper. Besides, the CheA-CsoR interaction also existed in proteins from several other bacterial species. Our results revealed a mechanism by which bacteria coordinately regulated chemotaxis and resistance to copper by CsoR.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics

    Transcriptome-wide identification of 5-methylcytosine by deaminase and reader protein-assisted sequencing

    Jiale Zhou, Ding Zhao ... Zhanjun Li
    Research Article

    5-Methylcytosine (m5C) is one of the posttranscriptional modifications in mRNA and is involved in the pathogenesis of various diseases. However, the capacity of existing assays for accurately and comprehensively transcriptome-wide m5C mapping still needs improvement. Here, we develop a detection method named DRAM (deaminase and reader protein assisted RNA methylation analysis), in which deaminases (APOBEC1 and TadA-8e) are fused with m5C reader proteins (ALYREF and YBX1) to identify the m5C sites through deamination events neighboring the methylation sites. This antibody-free and bisulfite-free approach provides transcriptome-wide editing regions which are highly overlapped with the publicly available bisulfite-sequencing (BS-seq) datasets and allows for a more stable and comprehensive identification of the m5C loci. In addition, DRAM system even supports ultralow input RNA (10 ng). We anticipate that the DRAM system could pave the way for uncovering further biological functions of m5C modifications.